Submissions from 2021
Cytokine-induced liver injury in coronavirus disease-2019 (COVID-19): untangling the knots., P. Anirvan, S. Narain, N. Hajizadeh, F. Z. Aloor, S. P. Singh, and S. K. Satapathy
Cytokine-induced liver injury in coronavirus disease-2019 (COVID-19): untangling the knots., P. Anirvan, S. Narain, N. Hajizadeh, F. Z. Aloor, S. P. Singh, and S. K. Satapathy
Severity of liver test abnormalities in coronavirus disease 2019 depends on comorbidities and predicts early in-hospital mortality., S. K. Satapathy, C. Kuntzen, H. Qiu, Y. Jiang, H. C. Bodenheimer, N. C. Roth, J. S. Hirsch, A. J. Trindade, D. E. Bernstein, and Northwell Health COVID-19 Research Consortium
Submissions from 2020
PRO: Portal Vein Thrombosis Impacts Liver Transplantation Outcomes, U. Agbim and S. K. Satapathy
Outcomes of Liver Transplant Recipients with Acute-on-Chronic Liver Failure Based on EASL-CLIF Consortium Definition: A Single-center Study, U. Agbim, A. Sharma, B. Maliakkal, S. Karri, M. Yazawa, W. Goldkamp, P. S. Podila, J. M. Vanatta, H. Gonzalez, S. K. Satapathy, and +3 additional authors
Effect of opioid treatment on clinical outcomes among cirrhotic patients in the United States, B. Ali, Y. Jiang, U. Agbim, S. K. Kedia, S. K. Satapathy, M. Barnes, B. Maliakkal, S. P. Nair, J. D. Eason, and H. C. Gonzalez
Liver injury in COVID-19: The hepatic aspect of the respiratory syndrome — what we know so far, P. Anirvan, P. Bharali, M. Gogoi, P. J. Thuluvath, S. P. Singh, and S. K. Satapathy
Review article: a treatment algorithm for patients with chronic liver disease and severe thrombocytopenia undergoing elective medical procedures in the United States, D. T. Dieterich, D. Bernstein, S. Flamm, P. J. Pockros, and N. Reau
Nafld epidemiology, emerging pharmacotherapy, liver transplantation implications and the trends in the United States, C. Gadiparthi, M. Spatz, S. Greenberg, U. Iqbal, S. Kanna, S. K. Satapathy, A. Broder, and A. Ahmed
Randomized placebo-controlled trial of emricasan for non-alcoholic steatohepatitis-related cirrhosis with severe portal hypertension, G. Garcia-Tsao, J. Bosch, Z. Kayali, S. A. Harrison, M. F. Abdelmalek, E. Lawitz, S. K. Satapathy, M. Ghabril, S. Satapathy, B. Muellhaupt, and +63 additional authors
A randomized, placebo-controlled trial of emricasan in patients with NASH and F1-F3 fibrosis, S. A. Harrison, Z. Goodman, A. Jabbar, R. Vemulapalli, Z. H. Younes, B. Freilich, M. Y. Sheikh, J. M. Schattenberg, S. K. Satapathy, A. J. Sanyal, and +10 additional authors
Elevated Liver Biochemistries in Hospitalized Chinese Patients with Severe COVID-19: Systematic Review and Meta-analysis., A. J. Kovalic, G. Huang, P. J. Thuluvath, and S. K. Satapathy
Reply to Letter to the Editor: Elevated Liver Biochemistries in Hospitalized Chinese Patients With Severe COVID-19: Systematic Review and Meta-Analysis., A. J. Kovalic, G. Huang, P. J. Thuluvath, and S. K. Satapathy
Thromboelastography versus standard coagulation testing in the assessment and reversal of coagulopathy among cirrhotics: a systematic review and meta-analysis, A. J. Kovalic, M. A. Khan, D. Malaver, M. J. Whitson, L. W. Teperman, D. E. Bernstein, A. Singal, and S. K. Satapathy
Systematic review with meta-analysis: abnormalities in the International Normalised Ratio (INR) do not correlate with periprocedural bleeding events among patients with cirrhosis, A. J. Kovalic, C. N. Majeed, N. S. Samji, P. J. Thuluvath, and S. K. Satapathy
Prevalence of chronic liver disease in patients with COVID-19 and their clinical outcomes: a systematic review and meta-analysis, A. J. Kovalic, S. K. Satapathy, and P. J. Thuluvath
Accuracy of Noninvasive Fibrosis Scoring Systems in African American and White Patients With Nonalcoholic Fatty Liver Disease, H. K. Marella, Y. K. Reddy, Y. Jiang, S. Ganguli, P. S. Podila, P. D. Snell, A. J. Kovalic, G. Cholankeril, A. K. Singal, S. K. Satapathy, and +2 additional authors
Natural History of Non-Alcoholic Fatty Liver Disease: A Study With Paired Liver Biopsies, Y. K. Reddy, H. K. Marella, Y. Jiang, S. Ganguli, P. Snell, P. S. Podila, B. Maliakkal, and S. K. Satapathy
Provider Attitudes and Practice Patterns for Direct-Acting Antiviral Therapy for Patients With Hepatocellular Carcinoma, N. E. Rich, J. D. Yang, P. V. Perumalswami, N. Alkhouri, W. Jackson, N. D. Parikh, N. Mehta, R. Salgia, S. K. Satapathy, A. G. Singal, and +37 additional authors
Treatment Options for Thrombocytopenia in Patients with Chronic Liver Disease Undergoing a Scheduled Procedure, S. Saab, D. Bernstein, T. Hassanein, M. Kugelmas, and P. Kwo
Similarities and Differences Between Nonalcoholic Steatohepatitis and Other Causes of Cirrhosis, N. S. Samji, R. Heda, A. J. Kovalic, and S. K. Satapathy
Peri-transplant management of nonalcoholic fatty liver disease in liver transplant candidates, N. S. Samji, R. Heda, and S. K. Satapathy
Racial Disparities in Diagnosis and Prognosis of Nonalcoholic Fatty Liver Disease, N. S. Samji, P. D. Snell, A. K. Singal, and S. K. Satapathy
Treating Portopulmonary Hypertension with Macitentan: Smoking Gun or Magic bullet?, S. K. Satapathy and B. L. Da
A pilot study of ex-vivo MRI-PDFF of donor livers for assessment of steatosis and predicting early graft dysfunction, S. K. Satapathy, H. C. Gonzalez, J. Vanatta, A. Dyer, W. Angel, S. S. Nouer, M. Kocak, S. K. Kedia, Y. Jiang, J. D. Eason, and +11 additional authors
Posttransplant Outcome of Lean Compared With Obese Nonalcoholic Steatohepatitis in the United States: The Obesity Paradox, S. K. Satapathy, Y. Jiang, U. Agbim, C. Wu, D. E. Bernstein, L. W. Teperman, S. K. Kedia, G. P. Aithal, K. R. Bhamidimarri, A. K. Singal, and +11 additional authors
African Americans have a distinct clinical and histologic profile with lower prevalence of NASH and advanced fibrosis relative to Caucasians., S. K. Satapathy, H. K. Marella, R. P. Heda, S. Ganguli, Y. Kirthi Reddy, P. S. B. Podila, I. Clark, and B. Maliakkal
Predicting Harmful Alcohol Relapse after Liver Transplant: The HALT Score., S. K. Satapathy, C. Thornburgh, R. Heda, Y. Jiang, S. K. Kedia, S. P. Nair, J. D. Eason, and D. Maluf
Role of Nutraceuticals in COVID-19 Mediated Liver Dysfunction., M. Sikander, S. Malik, A. Rodriguez, M. M. Yallapu, A. S. Narula, S. K. Satapathy, V. Dhevan, S. C. Chauhan, and M. Jaggi
Increasing Burden of Acute-On-Chronic Liver Failure among Alcohol-Associated Liver Disease in the Young Population in the United States, A. K. Singal, S. Arora, R. J. Wong, S. K. Satapathy, V. H. Shah, Y. F. Kuo, and P. S. Kamath
Hepatitis C remains leading indication for listings and receipt of liver transplantation for hepatocellular carcinoma, A. K. Singal, S. K. Satapathy, N. Reau, R. Wong, and Y. F. Kuo
What GI Physicians Need to Know During COVID-19 Pandemic, P. J. Thuluvath, J. J. Alukal, N. Ravindran, and S. K. Satapathy
Use of HCV-Positive Livers in HCV-Negative Recipients., P. J. Thuluvath, D. A. Bruno, J. Alukal, S. K. Satapathy, A. J. Thuluvath, and T. Zhang
Use of HCV-Positive Livers in HCV-Negative Recipients., P. J. Thuluvath, D. A. Bruno, J. Alukal, S. K. Satapathy, A. J. Thuluvath, and T. Zhang
Association between post-transplant donor-specific antibodies and recipient outcomes in simultaneous liver–kidney transplant recipients: single-center, cohort study, M. Yazawa, O. Cseprekal, R. A. Helmick, M. Talwar, V. Balaraman, P. S. Podila, U. A. Agbim, B. Maliakkal, S. K. Satapathy, M. Z. Molnar, and +5 additional authors
Lack of Association between Pretransplant Donor-Specific Antibodies and Posttransplant Kidney Outcomes in Simultaneous Liver-Kidney Transplant Recipients with Rabbit Anti-Thymocyte Globulin Induction and Steroid-Free Protocol, M. Yazawa, O. Cseprekal, R. A. Helmick, M. Talwar, V. Balaraman, P. S. Podila, U. A. Agbim, B. Maliakkal, S. K. Satapathy, M. Z. Molnar, and +5 additional authors
Association between longer hospitalization and development of de novo donor specific antibodies in simultaneous liver–kidney transplant recipients, M. Yazawa, O. Cseprekal, R. A. Helmick, M. Talwar, V. Balaraman, P. S. Podila, S. Fossey, S. K. Satapathy, J. D. Eason, and M. Z. Molnar
Kidney Graft Outcomes in High Immunological Risk Simultaneous Liver-Kidney Transplants, M. Yazawa, S. K. Satapathy, and M. Z. Molnar
Prevalence and Profile of Nonalcoholic Fatty Liver Disease in Lean Adults: Systematic Review and Meta-Analysis., S. Young, R. Tariq, J. Provenza, S. K. Satapathy, K. Faisal, A. Choudhry, S. L. Friedman, and A. K. Singal
Submissions from 2019
Real-World Study on Sofosbuvir-based Therapies in Asian Americans With Chronic Hepatitis C., C. Q. Pan, B. C. Tiongson, K.Q. Hu, S-H. B. Han, M. Tong, D. Chu, J. Park, T. P. Lee, K. R. Bhamidimarri, D. Wang, and +3 additional authors
Drug-Induced Liver Injury Due to Dulaglutide Use, A. V. Patel, P. M. Jotwani, and T. P. Lee
Efficacy and safety of ombitasvir/paritaprevir/ritonavir and dasabuvir with low-dose ribavirin in patients with chronic hepatitis C virus genotype 1a infection without cirrhosis, F. Poordad, S. Sedghi, P. J. Pockros, N. Ravendhran, R. Reindollar, M. R. Lucey, M. Epstein, L. Bank, D. Bernstein, D. R. Nelson, and +5 additional authors
Submissions from 2018
Nonalcoholic Fatty Liver Disease: An Expanding Health Care Epidemic Preface, D. E. Bernstein
Ribavirin dose management in HCV patients receiving ombitasvir/paritaprevir/ritonavir and dasabuvir with ribavirin, J. J. Feld, D. E. Bernstein, Z. Younes, H. Van Vlierberghe, L. Larsen, F. Tatsch, and P. Ferenci
Response to Perrella et al, P. Y. Kwo, M. L. Shiffman, and D. E. Bernstein
The cochrane review conclusion for Hepatitis C DAA therapies is wrong, P. Y. Kwo, M. L. Shiff, and D. E. Bernstein
Risk Factors for the Development of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis, Including Genetics, H. W. Lim and D. E. Bernstein
Glecaprevir/Pibrentasvir in patients with hepatitis C virus genotype 1 or 4 and past direct-acting antiviral treatment failure, F. Poordad, S. Pol, A. Asatryan, M. Buti, D. Shaw, C. Hezode, F. Felizarta, R. W. Reindollar, D. E. Bernstein, F. J. Mensa, and +10 additional authors
A phase III study evaluating the efficacy and safety of remimazolam (CNS 7056) compared with placebo and midazolam in patients undergoing colonoscopy., D. K. Rex, R. Bhandari, T. Desta, M. P. DeMicco, C. Schaeffer, K. Etzkorn, C. F. Barish, R. Pruitt, B. D. Cash, D. Bernstein, and +3 additional authors
Extracorporeal cellular therapy (ELAD) in severe alcoholic hepatitis: A multinational, prospective, controlled, randomized trial, J. Thompson, N. Jones, A. Al-Khafaji, S. Malik, D. Reich, S. Munoz, R. MacNicholas, T. Hassanein, A. Duddempudi, R. Subramanian, and +33 additional authors
Diagnosis and Evaluation of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis, Including Noninvasive Biomarkers and Transient Elastography, E. Tsai and T. P. Lee
Submissions from 2017
Seladelpar (MBX-8025), a selective PPAR-δ agonist, in patients with primary biliary cholangitis with an inadequate response to ursodeoxycholic acid: a double-blind, randomised, placebo-controlled, phase 2, proof-of-concept study., D. Jones, P. F. Boudes, M. G. Swain, C. L. Bowlus, M. R. Galambos, B. R. Bacon, Y. Doerffel, N. Gitlin, D. E. Bernstein, G. M. Hirschfield, and +26 additional authors
Glecaprevir and Pibrentasvir for 12 Weeks for Hepatitis C Virus Genotype 1 Infection and Prior Direct-Acting Antiviral Treatment, F. Poordad, F. Felizarta, A. Asatryan, M. S. Sulkowski, R. W. Reindollar, C. S. Landis, S. C. Gordon, S. L. Flamm, D. E. Bernstein, F. J. Mensa, and +6 additional authors
Asian-Pacific Association for the Study of the Liver (APASL) consensus guidelines on invasive and non-invasive assessment of hepatic fibrosis: a 2016 update, G. Shiha, A. Ibrahim, A. Helmy, S. K. Sarin, M. Omata, A. Kumar, D. Bernstien, H. Maruyama, V. Saraswat, Y. Chawla, S. Hamid, Z. Abbas, P. Bedossa, P. Sakhuja, M. Elmahatab, S. G. Lim, L. Lesmana, J. Sollano, J.D. Jia, and M. Kumar
Submissions from 2016
Sustained virologic response of 100% in HCV genotype 1b patients with cirrhosis receiving ombitasvir/paritaprevir/r and dasabuvir for 12weeks, J. J. Feld, C. Moreno, R. Trinh, E. Tam, S. Bourgeois, Y. Horsmans, M. Elkhashab, D. E. Bernstein, N. S. Shulman, F. Poordad, and +7 additional authors
Efficacy of Sofosbuvir, Velpatasvir, and GS-9857 in Patients With Hepatitis C Virus Genotype 2, 3, 4, or 6 Infections in an Open-Label, Phase 2 Trial, E. J. Gane, K. V. Kowdley, D. Pound, C. A.M. Stedman, M. Davis, K. Etzkorn, S. C. Gordon, D. Bernstein, P. Y. Kwo, M. H. Nguyen, and +14 additional authors
Simeprevir Plus Sofosbuvir (12 and 8 Weeks) in Hepatitis C Virus Genotype 1-Infected Patients Without Cirrhosis: OPTIMIST-1, a Phase 3, Randomized Study, P. Kwo, N. Gitlin, R. Nahass, D. Bernstein, K. Etzkorn, S. Rojter, E. Schiff, M. Davis, P. Ruane, J. Witek, and +8 additional authors
Efficacy of Direct-Acting Antiviral Combination for Patients with Hepatitis C Virus Genotype 1 Infection and Severe Renal Impairment or End-Stage Renal Disease, P. J. Pockros, K. R. Reddy, P. S. Mantry, E. Cohen, M. Bennett, M. S. Sulkowski, D. E. Bernstein, D. E. Cohen, N. S. Shulman, E. Lawitz, and +4 additional authors
Submissions from 2015
Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid, G. M. Hirschfield, A. Mason, V. Luketic, K. Lindor, S. C. Gordon, M. Mayo, K. V. Kowdley, C. Vincent, H. C. Bodhenheimer Jr., D. Shapiro, and +8 additional authors
Daclatasvir and asunaprevir plus peginterferon alfa and ribavirin in HCV genotype 1 or 4 non-responders, D. Jensen, K. E. Sherman, C. Hezode, S. Pol, S. Zeuzem, V. de Ledinghen, A. Tran, M. Elkhashab, D. Bernstein, S. Noviello, and +13 additional authors
All-Oral 12-Week Treatment With Daclatasvir Plus Sofosbuvir in Patients With Hepatitis C Virus Genotype 3 Infection: ALLY-3 Phase III Study, D. R. Nelson, J. N. Cooper, J. P. Lalezari, E. Lawitz, P. J. Pockros, N. Gitlin, B. F. Freilich, Z. H. Younes, D. Berastein, E. A. Hughes, and +15 additional authors
Submissions from 2014
Hepatitis B and C, A. T. Duddempudi and D. E. Bernstein
ABT-450/r-Ombitasvir and Dasabuvir with or without Ribavirin for HCV, P. Ferenci, D. Bernstein, J. Lalezari, D. Cohen, Y. Luo, C. Cooper, E. Tam, R. T. Marinho, N. Tsai, K. R. Reddy, and +19 additional authors
Ledipasvir and Sofosbuvir for 8 or 12 Weeks for Chronic HCV without Cirrhosis, K. V. Kowdley, S. C. Gordon, K. R. Reddy, L. Rossaro, D. E. Bernstein, E. Lawitz, M. L. Shiffman, E. Schiff, R. Ghalib, M. W. Fried, and +15 additional authors